The PAM50 breast cancer signature developed at the University of Utah and Huntsman Cancer Institute received FDA approval and will launch at ARUP Laboratories in Salt Lake City.
Cells with a mutation in the gene called K-Ras found mostly in cancers with the worst prognoses behave in ways that subvert the normal mechanisms of cell death